Drugs / BIIB111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03584165 | Jun 2018 → Jun 2026 | choroideremia, retinitis pigmentosa | NightstaRx Ltd, a Biogen Company | Completed | No outcome recorded |
| Phase 3 | NCT03496012 | Dec 2017 → Dec 2020 | choroideremia | Biogen | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03496012 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)” NCT03496012 ↗ |
| Route | Other | “through sub-retinal injection” NCT03496012 ↗ |